Eli Lilly's experimental drug eloralintide, when combined with Zepbound, achieved an average weight loss of 23.3% over approximately 11 months in patients with Type 2 diabetes. This compares to 14.8% for Zepbound alone. However, 11-27% of patients discontinued the combination treatment due to side effects, raising tolerability concerns. Lilly plans to advance the treatment into late-stage trials later this year.